8-K: Precision BioSciences Reports 2023 Financial Results and Advances In Vivo Gene Editing Programs

Precision BioSciences announced its fourth quarter and full year 2023 financial results, highlighting progress in its in vivo gene editing programs and strategic financial moves.

Summary

• Precision BioSciences reported a net loss of $16.3 million for the fourth quarter of 2023, compared to a net loss of $28.5 million for the same period in 2022.
• The company's full-year 2023 net loss was $61.3 million, an improvement from the $111.6 million loss in 2022.
• Revenue for the fourth quarter of 2023 was $7.0 million, down from $10.6 million in the same quarter of 2022, primarily due to decreased collaboration revenue.
• Full-year 2023 revenue was $48.7 million, up from $25.1 million in 2022, driven by increased revenue from the Prevail and Novartis agreements.
• Research and development expenses increased to $13.4 million in Q4 2023 and $53.4 million for the full year, reflecting the advancement of the PBGENE-HBV and PBGENE-PMM programs.
• The company completed licensing agreements for its divested CAR T assets, securing nearly $50 million in upfront and potential near-term payments.
• A $40 million public offering was completed, extending the company's cash runway into the second half of 2026.
• Precision BioSciences expects to submit IND and/or CTA filings for PBGENE-HBV in 2024 and PBGENE-PMM in 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the company's strategic shift to in vivo gene editing, successful monetization of CAR T assets, and strengthened financial position. The progress in clinical programs and regulatory feedback further contribute to the positive outlook.

Positives

• The company successfully monetized its CAR T assets, generating significant upfront and potential near-term revenue.
• The $40 million public offering has strengthened the balance sheet and extended the cash runway.
• The company is making significant progress in its in vivo gene editing programs, with IND/CTA filings expected for PBGENE-HBV in 2024 and PBGENE-PMM in 2025.
• Regulatory feedback from the FDA and other agencies has provided clarity for the PBGENE-HBV program.
• The ARCUS technology has demonstrated high efficiency gene insertion in non-dividing cells.
• The company has reduced its net loss compared to the previous year.

Negatives

• Revenue decreased in the fourth quarter of 2023 compared to the same period in 2022.
• The company continues to operate at a loss, although the loss has decreased year-over-year.
• Research and development expenses have increased, reflecting the costs of advancing the in vivo gene editing programs.

Risks

• The company's ability to become profitable is uncertain.
• There are risks associated with the company's capital requirements and ability to raise additional capital.
• The success of the company's programs and product candidates is not guaranteed.
• There is competition in the gene editing, biopharmaceutical, and biotechnology fields.
• The company is dependent on its ARCUS technology.
• There are risks associated with clinical trials, regulatory approvals, and manufacturing.
• The company's cash runway is dependent on continued fiscal and operating discipline, and the availability of its ATM facility and credit.

Future Outlook

Precision BioSciences plans to advance PBGENE-HBV and PBGENE-PMM towards IND and/or CTA filings in 2024 and 2025, respectively, and commence a new gene insertion program. The company anticipates presenting and publishing new data that further differentiates ARCUS as a potential best-in-class tool for high efficiency gene insertion. The company expects its cash runway to extend into the second half of 2026.

Management Comments

• Michael Amoroso, President and Chief Executive Officer of Precision BioSciences, stated that 2023 was a transformative year for the company as it transitioned to an in vivo gene editing company.
• Mr. Amoroso also noted that the company is well positioned to execute against its objectives, having received regulatory feedback from the FDA and other agencies.

Industry Context

This announcement reflects the broader trend in the biotechnology industry towards gene editing therapies, particularly in vivo approaches. Precision BioSciences is positioning itself as a leader in this space with its ARCUS platform, competing with other gene editing companies and technologies like CRISPR-Cas.

Comparison to Industry Standards

• Precision BioSciences' focus on in vivo gene editing aligns with the industry's shift towards more direct and efficient therapeutic approaches, contrasting with ex vivo methods used by companies like CRISPR Therapeutics and Vertex Pharmaceuticals.
• The company's ARCUS platform, with its unique cutting mechanism and smaller size, is positioned as a differentiator compared to CRISPR-Cas systems, which require guide RNAs.
• The reported 40-45% gene insertion efficiency in non-dividing cells in non-human primates is a notable achievement, potentially exceeding the efficiency of other gene editing technologies in similar contexts.
• The licensing deals for CAR T assets are a strategic move to monetize non-core assets, similar to other biotech companies that focus on specific therapeutic areas.
• The $40 million public offering is a common strategy for biotech companies to secure funding for clinical development, comparable to capital raises by other companies in the sector.

Stakeholder Impact

• Shareholders will benefit from the extended cash runway and the potential for future growth.
• Employees will be impacted by the company's focus on in vivo gene editing and the advancement of its programs.
• Patients with chronic hepatitis B and primary mitochondrial myopathy may benefit from the development of new treatments.
• Partners and collaborators will be impacted by the company's progress in its gene editing programs.

Next Steps

• Precision BioSciences plans to submit IND and/or CTA filings for PBGENE-HBV in 2024.
• The company plans to submit IND and/or CTA filings for PBGENE-PMM in 2025.
• Precision BioSciences will commence a new gene insertion program.
• The company anticipates presenting and publishing new data further differentiating ARCUS.
• The company will continue to advance its partnered gene editing programs.

Key Dates

Keywords

gene editing, in vivo, ARCUS, PBGENE-HBV, PBGENE-PMM, CAR T, clinical trials, IND, CTA, biotechnology, hepatitis B, mitochondrial myopathy